The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects
Abstract
UNLABELLED: The objectives of this study were to examine the effective dose range and the test-retest reliability of florbetapir F 18 using, first, visual assessment by independent raters masked to clinical information and, second, semiautomated quantitative measures of cortical target area to cerebellum standardized uptake value ratios (SUVr) as primary outcome measures. Visual ratings of PET image quality and tracer retention or β-amyloid (Aβ) binding expressed as SUVrs were compared after intravenous administration of either 111 MBq (3 mCi) or 370 MBq (10 mCi) of florbetapir F 18 in patients with Alzheimer's disease (AD) (n = 9) and younger healthy controls (YHCs) (n = 11). In a separate set of subjects (AD, n = 10; YHCs, n = 10), test-retest reliability was evaluated by comparing intrasubject visual read ratings and SUVrs for 2 PET images acquired within 4 wk of each other. RESULTS: There were no meaningful differences between the 111-MBq (3-mCi) and 370-MBq (10-mCi) dose in the visual rating or SUVr. The difference in the visual quality across 111 and 370 MBq showed a trend toward lower image quality, but no statistical significance was achieved (t test; t(1) = -1.617, P = 0.12) in this relatively small sample of subjects. At both dose levels, visual ratings of amyloid burden identified 100% of AD subjects as Aβ-positive and 100% of YHCs as Aβ-negative. Mean intrasubject test-retest variability for cortical average SUVrs with the cerebellum as a reference over the 50- to 70-min period was 2.4% ± 1.41% for AD subjects and 1.5% ± 0.84% for controls. The overall SUVr test-retest correlation coefficient was 0.99. The overall κ-statistic for test-retest agreement for Aβ classification of the masked reads was 0.89 (95% confidence interval, 0.69-1.0). CONCLUSION: Florbetapir F 18 appears to have a wide effective dose range and a high test-retest reliability for both quantitative (SUVr) values and visual assessment of the ligand. These imaging performance properties provide important technical information on the use of florbetapir F 18 and PET to detect cerebral amyloid aggregates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Measurement of Observer Agreement for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529310 · Cited by 81,148
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 1×
“In view of accumulating evidence (30,31) clearly showing that amyloid deposition takes place years before the onset of dementia, subjects with mild cognitive impairment and clinically healthy elderly can have significant amyloid levels both on PET scans and at autopsy.”
BackgroundResearch criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Statistical Parametric Mapping: The Analysis of Functional Brain Images
Penny, W. D., Friston, K. J., Ashburner, J., Kiebel, S. J., & Thomas, N. (2007) · UCL Discovery (University College London) · Cited by 3,656
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
The Clinical Diagnosis of Alzheimer's Disease
Wade, J. P. H., Mirsen, T. R., Hachinski, V. C., Fisman, M., Lau, C., & Merskey, H. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520130016010 · Cited by 1,374
Cited by
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855
Self-citationAmyloid deposition, hypometabolism, and longitudinal cognitive decline
Landau, S. M., Mintun, M. A., Joshi, A. D., Koeppe, R. A., Petersen, R. C., Aisen, P. S., Weiner, M. W., Jagust, W. J., & Initiative, F. T. A. D. N. (2012) · Annals of Neurology · doi:10.1002/ana.23650 · Cited by 727
Self-citationAssociation Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition
Gottesman, R. F., Schneider, A. L. C., Zhou, Y., Coresh, J., Green, E., Gupta, N., Knopman, D. S., Mintz, A., Rahmim, A., Sharrett, A. R., et al. (2017) · JAMA · doi:10.1001/jama.2017.3090 · Cited by 650
Cascading network failure across the Alzheimer’s disease spectrum
Jones, D. T., Knopman, D. S., Gunter, J. L., Graff-Radford, J., Vemuri, P., Boeve, B. F., Petersen, R. C., Weiner, M. W., & Jack, C. R. (2016) · Brain · doi:10.1093/brain/awv338 · Cited by 540
Landau, S. M., Breault, C., Joshi, A. D., Pontecorvo, M., Mathis, C. A., Jagust, W. J., & Mintun, M. A. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.109009 · Cited by 462
Self-citationIn vivo staging of regional amyloid deposition
Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004643 · Cited by 440
Self-citationPalmqvist, S., Mattsson, N., Hansson, O., & Initiative, F. T. A. D. N. (2016) · Brain · doi:10.1093/brain/aww015 · Cited by 400
Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid
Landau, S. M., Lu, M., Joshi, A. D., Pontecorvo, M., Mintun, M. A., Trojanowski, J. Q., Shaw, L. M., Jagust, W. J., & Initiative, F. T. A. D. N. (2013) · Annals of Neurology · doi:10.1002/ana.23908 · Cited by 401
Self-citationLandau, S. M., Fero, A., Baker, S. L., Koeppe, R., Mintun, M., Chen, K., Reiman, E. M., & Jagust, W. J. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.148981 · Cited by 364
Self-citationGut microbiome composition may be an indicator of preclinical Alzheimer’s disease
Ferreiro, A. L., Choi, J., Ryou, J., Newcomer, E. P., Thompson, R., Bollinger, R. M., Hall-Moore, C., Ndao, I. M., Sax, L., Benzinger, T. L. S., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo2984 · Cited by 356
Moscoso, A., Grothe, M. J., Ashton, N. J., Karikari, T. K., Lantero Rodríguez, J., Snellman, A., Suárez-Calvet, M., Blennow, K., Zetterberg, H., Schöll, M., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4986 · Cited by 310
Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers
Initiative, T. A. D. N., Landau, S. M., Thomas, B. A., Thurfjell, L., Schmidt, M., Margolin, R., Mintun, M., Pontecorvo, M., Baker, S. L., & Jagust, W. J. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2753-3 · Cited by 294
Self-citationAmyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease
Mormino, E. C., Betensky, R. A., Hedden, T., Schultz, A. P., Ward, A., Huijbers, W., Rentz, D. M., Johnson, K. A., Sperling, R. A., & For the Alzheimer's Disease Neuroimaging Initiative, T. A. I. B. A. L. F. S. O. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000431 · Cited by 293
In vivo staging of regional amyloid deposition
Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., Stern, Y., & Initiative, A. D. N. (2022) · DZNE Pub · doi:10.7916/0vj1-4c02 · Cited by 289
Johnson, K. A., Sperling, R. A., Gidicsin, C. M., Carmasin, J. S., Maye, J. E., Coleman, R. E., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.10.007 · Cited by 270
Self-citationMAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER’S DISEASE: DESIGN AND BASELINE DATA
Vellas, B., Gillette-Guyonnet, S., Touchon, J., Dantoine, T., Dartigues, J. F., Cuffi, M. N., Bordes, S., Gasnier, Y., Robert, P., Bories, L., et al. (2014) · The Journal Of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2014.34 · Cited by 255
Mattsson, N., Insel, P. S., Donohue, M., Landau, S., Jagust, W. J., Shaw, L. M., Trojanowski, J. Q., Zetterberg, H., Blennow, K., & Weiner, M. W. (2015) · Brain · doi:10.1093/brain/awu367 · Cited by 237
Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach
Initiative, F. T. A. D. N., Royse, S. K., Minhas, D. S., Lopresti, B. J., Murphy, A., Ward, T., Koeppe, R. A., Bullich, S., DeSanti, S., Jagust, W. J., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00836-1 · Cited by 237
“val of mean cortical FBP SUVRs relative to the whole cerebellum in a young control group [19] and trans-”
BackgroundMethodNavitsky, M., Joshi, A. D., Kennedy, I., Klunk, W. E., Rowe, C. C., Wong, D. F., Pontecorvo, M. J., Mintun, M. A., & Devous, M. D. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.1353 · Cited by 229
“Previous amyloid imaging studies have explored methods to reduce test/ retest variance [10], improve correspondence with tissue pathology at autopsy [11,12], and measure longitudinal change [13].”
BackgroundSelf-citationQuantification of amyloid PET for future clinical use: a state-of-the-art review
Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226
Klein, G., Delmar, P., Voyle, N., Rehal, S., Hofmann, C., Abi-Saab, D., Andjelkovic, M., Ristic, S., Wang, G., Bateman, R., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0559-z · Cited by 212
Head‐to‐head comparison of leading blood tests for Alzheimer's disease pathology
(2024) · doi:10.1002/alz.14315 · Cited by 199
A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease
Nordberg, A., Carter, S. F., Rinne, J., Drzezga, A., Brooks, D. J., Vandenberghe, R., Perani, D., Forsberg, A., Långström, B., Scheinin, N., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2237-2 · Cited by 186
“Several new (18)F-labelled amyloid tracers such as [(18)F] florbetaben [15], [(18)F]florbetapir [16], [(18)F]flutemetamol [17] and [(18)F]AZD4694 [18] have been investigated.”
MethodApolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging
Jagust, W. J., Landau, S. M., & Initiative, F. T. A. D. N. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.3266-12.2012 · Cited by 162
“10 for the cortical/cerebellar ratio in a separate study represented the upper limit of the 95% confidence interval for a group of normal young subjects (Joshi et al., 2012) and was also the value below which no pathological evidence of plaque A deposition greater than “low likelihood” was found in an imaging–autopsy…”
BackgroundResultAlzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
Bucci, M., Chiotis, K., Nordberg, A., & Initiative, F. T. A. D. N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01263-2 · Cited by 140
Yew, B., Nation, D. A., & Initiative, F. T. A. D. N. (2017) · Brain · doi:10.1093/brain/awx112 · Cited by 133
Parker, T. D., Slattery, C. F., Zhang, J., Nicholas, J. M., Paterson, R. W., Foulkes, A. J. M., Malone, I. B., Thomas, D. L., Modat, M., Cash, D. M., et al. (2018) · Human Brain Mapping · doi:10.1002/hbm.24056 · Cited by 122
“In particular, relating measurements of cortical grey matter microstructure with data from in vivo PET radiotracers of beta-amyloid (Clark et al., 2011; Joshi et al., 2012; Klunk et al., 2004) and tau deposition (Marqui e et al.”
BackgroundInfluentialAltered whole-brain white matter networks in preclinical Alzheimer's disease
Fischer, F. U., Wolf, D., Scheurich, A., & Fellgiebel, A. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.06.007 · Cited by 105
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K. V., & Chételat, G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.03.014 · Cited by 99
Association of Sleep and β-Amyloid Pathology Among Older Cognitively Unimpaired Adults
Insel, P. S., Mohlenhoff, B. S., Neylan, T. C., Krystal, A. D., & Mackin, R. S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.17573 · Cited by 97
Flortaucipir F 18 quantitation using parametric estimation of reference signal intensity.
Southekal, S., Devous, M. D., Kennedy, I., Navitsky, M., Lu, M., Joshi, A. D., Pontecorvo, M. J., & Mintun, M. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200006 · Cited by 92
“some of these concerns, the whole cerebellum (including cerebellar white matter [WM]) was validated for 18F-florbetapir in an autopsy study (9) and used to determine an amyloid (18F-florbetapir) positivity threshold (10).”
MethodSelf-citationToledo, J. B., Bjerke, M., Da, X., Landau, S. M., Foster, N. L., Jagust, W., Jack, C., Weiner, M., Davatzikos, C., Shaw, L. M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4829 · Cited by 88
Test-retest reproducibility for the tau PET imaging agent flortaucipir F 18.
Devous, M. D., Joshi, A. D., Navitsky, M., Southekal, S., Pontecorvo, M. J., Shen, H., Lu, M., Shankle, W. R., Seibyl, J. P., Marek, K., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200691 · Cited by 79
Self-citationDong, J. W., Jelescu, I. O., Ades-Aron, B., Novikov, D. S., Friedman, K., Babb, J. S., Osorio, R. S., Galvin, J. E., Shepherd, T. M., & Fieremans, E. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.01.009 · Cited by 70
Insel, P. S., Hansson, O., & Mattsson-Carlgren, N. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3780 · Cited by 68
Palmqvist, S., Insel, P. S., Zetterberg, H., Blennow, K., Brix, B., Stomrud, E., Initiative, T. A. D. N., study, T. S. B., Mattsson, N., & Hansson, O. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.014 · Cited by 65
Weigand, A. J., Thomas, K. R., Bangen, K. J., Eglit, G. M. L., Delano‐Wood, L., Gilbert, P. E., Brickman, A. M., Bondi, M. W., & Initiative, F. T. A. D. N. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12173 · Cited by 59
Su, Y., Blazey, T. M., Owen, C. J., Christensen, J. J., Friedrichsen, K., Joseph-Mathurin, N., Wang, Q., Hornbeck, R. C., Ances, B. M., Snyder, A. Z., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152082 · Cited by 56
“While MR data is generally available for most of the ongoing neuroimaging studies, quantification methods that does not require MR [37–39] have their advantages and warrant further investigation.”
MethodBangen, K. J., Initiative, F. T. A. D. N., Clark, A. L., Werhane, M., Edmonds, E. C., Nation, D. A., Evangelista, N., Libon, D. J., Bondi, M. W., & Delano-Wood, L. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150900 · Cited by 51
Degenhardt, E. K., Witte, M. M., Case, M. G., Yu, P., Henley, D. B., Hochstetler, H. M., D’Souza, D. N., & Trzepacz, P. T. (2016) · Psychosomatics · doi:10.1016/j.psym.2015.12.002 · Cited by 48
Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls
Mattsson, N., Insel, P. S., Donohue, M., Jagust, W., Sperling, R., Aisen, P., & Weiner, M. W. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4530 · Cited by 45
Iaccarino, L., Sala, A., Caminiti, S. P., Presotto, L., Perani, D., & Initiative, F. T. A. D. N. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190954 · Cited by 40
Longitudinal validity of PET‐based staging of regional amyloid deposition
Jelistratova, I., Teipel, S. J., & Grothe, M. J. (2020) · Human Brain Mapping · doi:10.1002/hbm.25121 · Cited by 39
Metadata
- Authors
- Joshi, A. D., Pontecorvo, M. J., Clark, C. M., Carpenter, A. P., Jennings, D. L., Sadowsky, C. H., Adler, L. P., Kovnat, K. D., Seibyl, J. P., Arora, A., Saha, K., Burns, J. D., Lowrey, M. J., Mintun, M. A., Skovronsky, D. M., & the Florbetapir F 18 Study Investigators
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2012-02-13
- Volume
- 53
- Issue
- 3
- Pages
- 378-384
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2166536611
- Cited by
- 391
- References
- 31
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.